Pod Insights Masters of Scale Why we keep failing to eradicate this disease, with YouTuber John Green About this episode John Green has spent his career telling stories — through novels, YouTube videos, and educational projects like Crash Course. Now, he’s on a mission to eliminate tuberculosis: a curable disease that still kills more than a million people every year. In this episode, Green joins host Jeff Berman to talk about how we could scale solutions to this global health crisis — and how to leverage obsession, creativity, and community to take on monumental challenges.
Link to Everything is Tuberculosis https://everythingistb.com/
Link to Henry’s YouTube https://www.youtube.com/channel/UCMjyZU6hnZk0ZUaMHSgsPdg
Subscribe to the Masters of Scale weekly newsletter: https://mastersofscale.com/subscribe
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Transcript 6,627 words · 12 speakers
0:01 Speaker 00 We've all spent money on something that seemed incredible but didn't live up to the hype. A kitchen gadget, a car. When it doesn't deliver, the disappointment is real. Marketers suffer from this too. Chasing metrics that look great but don't translate into revenue. LinkedIn calls that bull spend. Invest in what matters and reach the right buyers with LinkedIn Ads. You can target by company, industry, job title, and more. LinkedIn Ads also generates the highest ROAS of all major ad networks. Spend $250 on your first campaign on LinkedIn Ads and get a $250 credit for the next one. Just go to LinkedIn.com/Scale. That's LinkedIn.com/Scale.
0:44 Speaker 00 Terms and conditions apply. The very best founders I know are brilliant at building systems. They connect teams, they remove bottlenecks, and they eliminate single points of failure. And yet, when it comes to their own wealth, most are running a disconnected stack. A tax accountant here and a state attorney there, a wealth manager who doesn't talk to either one of them. Creative Planning was built to fix exactly that. One integrated team of tax professionals, state planners, investment specialists, all coordinated by a dedicated wealth manager who sees your full financial picture and keeps every piece working together.
1:27 Speaker 00 Proactive tax efficiency, estate strategy, investments, all under one roof. Creative Planning, where wealth works together. Learn more at creativeplanning.com/mastersofscale.
1:41 Speaker 01 AI is full of possibilities. Enterprises run on realities. That's why Pega combines the world's most powerful AI with the governance, transparency, and control enterprises demand. So you can move faster, adapt faster, and scale AI with confidence. All the power of AI, none of the uncertainty. Learn more at Pega.com/AI.
2:10 Speaker 02 We solve the problems we pay attention to. And if we feel like we're paying attention to a problem that not enough other people are paying attention to, that's really exciting in a lot of ways. It's also quite frustrating, right? It means that at dinner, you're a weird company because you only want to talk about one thing.
2:26 Speaker 00 If you've ever been an entrepreneur, or if you want to be one someday, I bet you can relate to what John Green is talking about here. That intense hyper-focus that happens when you are truly obsessed with an idea. In the business world, this can really help drive scale, but John is obsessed with something that isn't about business, but offers lessons and inspiration for all of us. He's trying to help eradicate an entire disease.
2:59 Speaker 02 It would take $25 billion a year, according to the UN, to really eradicate tuberculosis globally, which, I mean, is a lot of money and not a lot of money, right? It's a lot of money in global health. It's not a lot of money necessarily in Silicon Valley.
3:11 Speaker 00 This week on the show, author John Green is here to talk about tuberculosis. It's one of the deadliest afflictions in human history, and even though we've ways to cure it, more than a million people a year still die from it. John's unrelenting quest to solve this problem is a fascinating case study in how to scale solutions and spur change.
3:33 Speaker 03 You've got to have incredible talent at every position.
3:37 Speaker 04 There are fires burning when you're going home. Can you believe it?
3:40 Speaker 05 Such an idiot. And then you go back to, this is totally going to be amazing.
3:45 Speaker 04 There are so many easy ways. I have no idea what to do.
3:48 Speaker 05 Sorry, we made a mistake.
3:49 Speaker 04 But you have to time it right. Oops. Working out of a three-bedroom apartment.
3:54 Speaker 06 Stuff that just seems absolutely nutballs. 10 years later, we're like, well, that's just how you do it. We haven't made it. Just how you do it.
4:03 Speaker 00 This is Masters of Scale.
4:09 Speaker 00 I'm Jeff Berman, your host. John Green is a popular content creator behind Crash Course and Vlogbrothers alongside his brother Hank. He's also written popular novels like The Fault in Our Stars and Turtles All the Way Down. His latest is called Everything is Tuberculosis, and unfortunately, it's not another work of fiction. It reveals the complex history of tuberculosis and the ongoing fight against this deadly global disease.
4:39 Speaker 00 John, welcome to Masters of Scale.
4:40 Speaker 02 Thanks so much for having me.
4:42 Speaker 00 Yeah, I'm super excited to have you, John. You've just written a book called Everything is Tuberculosis, and I think most people thought tuberculosis was already cured. So why in 2025 are we writing and reading about tuberculosis?
4:56 Speaker 02 Well, one of the great challenges we face together is that discovering a cure doesn't mean that everyone gets access to that cure. And we've seen that most glaringly in the case of tuberculosis, which has been curable since the 1950s. But in the decades since it became curable, we've allowed over 150 million people to die of it. And I think the reason I ultimately wanted to write this book is because I'm so fascinated by the question of how that can happen.
5:20 Speaker 00 Why is that the case?
5:21 Speaker 02 Well, first off, tuberculosis is not easy to cure. It's closer to curing cancer than it is to curing a sinus infection. It requires four to six months with the newest regimens of daily antibiotics. It's a disease that primarily affects the most impoverished people in the world. Anybody can get tuberculosis. It's airborne, but it disproportionately affects the world's poorest people. And we've just done a terrible job of building systems that reflect the reality that everybody's life has equal meaning. And so we unfortunately do a terrible job of getting the cure to the people who need it most. There are all kinds of reasons why that breaks down, from not developing good enough drugs, to not getting those drugs the last mile to the people who need them the most. But somewhere
6:04 Speaker 02 along the links in the chain, it keeps failing and failing and failing. And that's why we lose over a million people a year to TB.
6:10 Speaker 00 Of all the things that you could choose to spend time on, why has tuberculosis become such a mission for you?
6:17 Speaker 02 I very easily could have written a book about malaria, or about HIV, or about diabetes, or about cancer. I mean, tuberculosis is by no means the only disease of injustice. It's just that for me, it's the exemplary disease of injustice. It's an illness that has had a huge impact on our history. I mean, one out of every seven people or somewhere in that vicinity has died of tuberculosis of the people who've ever been born. And so it's a huge part of our history, but it's also a huge part of our present. And it really lays bare the truth of inequitable access to healthcare in our world, which is that we can come up with all the AI fueled cures that we want. But if we don't get those cures to the people who most need them, we're just fundamentally failing ourselves.
6:58 Speaker 00 And part of your story and part of the story of the book is about Sierra Leone. How did Sierra Leone become a country where you started spending time? And can you tell us how tuberculosis really came to be personal for you in that journey?
7:12 Speaker 02 Yeah, absolutely. So my wife and I visited Sierra Leone in 2019 with Partners in Health, a great nonprofit organization to learn about maternal health there. And then on the last day of our trip, the folks we were traveling with asked if we could visit a tuberculosis hospital because they had some cases they wanted to consult on. We went to this TB hospital and the moment we arrived, I was just grabbed by this kid named Henry, which is also my son's name. And he seemed to be about the same age as my son. He looked to be about nine years old. That's how old my kid was at the time. And Henry just started walking me all around the hospital. He was like the mayor of that place. Everywhere we went, people were shaking his hand and rubbing his head and picking him up and giving him hugs. And he was just an incredibly charismatic person. And then we made our way back to the
7:55 Speaker 02 doctors and nurses who were meeting and they kind of lovingly shooed him away. And I said, whose kid is that? Is that one of your kids? And they said, no, he's a patient. And he's actually one of the patients we're really concerned about because it turned out Henry was responding to antibiotics. That's why he looked relatively well. But they knew he wasn't responding to them well enough and that eventually his infection would roar back. And when it did, they just didn't have any tools to help him. And so it was really following Henry's story that, as you say, make this personal for me and help me understand that it's not just about a million deaths a year. It's the fact that each of those Million people who are going to die are incalculably valuable, have lives that are as rich and complex as my own, and their griefs grieve on the same universal bones, as Faulkner put it, as anyone else's.
8:39 Speaker 00 One of the lines in the book that really stuck with me is, "The cure is where the disease is not, and the disease is where the cure is not." Henry was at a hospital, so it would seem that the cure is there. What's the challenge there? What do we need to understand about why the cure is not where the disease is?
9:00 Speaker 02 The main challenge is cost. I mean, Henry was told over and over again that it just wasn't cost-effective to treat his particular tuberculosis, too complicated, too drug resistant. The real challenge for Henry was that he couldn't be treated with the first-line antibiotics. They failed very early on, then the second-line antibiotics failed, and then you end up with this incredibly toxic regimen of injectable drugs. And he endured that needlessly, because if he'd had access to a molecular test, they would have known from the beginning that Henry was also resistant to those drugs. And so he needed a personalized, tailored treatment in order to survive. And it was only because Dr. Tofara and the Sierra Leonean Ministry of Health ultimately came to the conclusion that
9:42 Speaker 02 he deserved that, and that it was worth the investment that Henry's here with us today.
9:47 Speaker 00 This is a show called Masters of Scale, and most of the time, we interview founders and CEOs, business leaders, or scaling companies or scaled companies, and we're helping our audience extract those lessons and insights so that they can do the same. I just want to scale the challenge for our audience here. Is it just a dollars question, if we had enough money, we could do this? Or are there other challenges here that we need to solve for?
10:12 Speaker 02 So absolutely, if we had enough money, we could do it. But it's a lot of money. It's like $25 billion a year, which, I mean, is a lot of money and not a lot of money, right? It's a lot of money in global health. It's not a lot of money necessarily in Silicon Valley sometimes, but it would take $25 billion a year, according to the UN, to really eradicate tuberculosis globally. The crisis is really everywhere. I mean, we have 10,000 cases of active TB in the United States every year. So there's no place that's immune to TB, but the epicenter of the crisis is India. Almost a third of the people who die of tuberculosis this year will die in India. There's also epicenters in Nigeria, in the Philippines, in Indonesia. Those are the biggest countries where there's really critical need. The highest rates we see of tuberculosis are in Lesotho, which is a small country in Southern Africa,
10:57 Speaker 02 where a lot of people work in mining. We know that any exposure to air pollutants makes tuberculosis worse. Also, in countries like in West Africa, like Sierra Leone, they have very high rates of tuberculosis because they have very high rates of impoverishment. We know that when we cut the rates of impoverishment, even without medical intervention, we cut the rates of TB. It's a resource problem on that level. There are also many other aspects to the problem, as I argue in the book, including a social dynamic that's really difficult to get past. We need to shrink the empathy gap between the rich world and the poor world. This is a huge problem. When we are proximal to suffering as a species, we are so generous. It's a shame that we need GoFundMe to be an addendum to the healthcare system in the
11:38 Speaker 02 United States, but think of how many GoFundMes have paid for everything from dog surgeries to life-saving organ donation operations. And yet, when we're distant from suffering, when we can create distance between ourselves and suffering, we're so much less generous, and we're much more likely, frankly, to be monstrous, to think that people are not really people, or to think that their lives are not as valuable as ours, or there's nothing we can do, or that our problems aren't about their problems. And so I think we have to shrink the empathy gap, one. That's one social problem.
12:09 Speaker 00 This empathy gap strikes me as an especially interesting challenge for us to take on. You help address it through what you do in media. Can you imagine other scaled solutions to closing the empathy gap or shrinking the empathy gap?
12:25 Speaker 02 Well, I think the biggest solution I've seen to shrinking the empathy gap, and look, I'm not going to say that it's perfect because I don't labor under the delusion that the social internet is good news, but is the social internet. People become proximal to all kinds of suffering that they weren't proximal to before, and that leads to action, it leads to collective action, leads to protest, leads to all kinds of social movements. Sometimes that stuff is messy and complicated, but it's at scale. And so that's why I've been trying to use my megaphone to get attention for tuberculosis is because I think that the social internet does work at scale. The problem is that people with the megaphones tend not to be people in impoverished communities. I mean, the poorest and most vulnerable among us are the people we're least likely to hear from.
13:10 Speaker 02 I think the solution at scale is some form of many-to-many conversation.
13:14 Speaker 00 As I think about how the tech world especially approaches these challenges, I'm sort of stuck on this question of is capitalism up to the task? I mean, I'm a capitalist. We have a flawed capitalism in this country, no doubt, but I believe it's the best economic system we have. I also acknowledge it doesn't solve every problem on its own. We have government for a reason, and we have shared public health goals globally for a reason. What more can capitalism do to solve the problem before we get to kind of the shared public health challenge for government?
13:47 Speaker 02 Well, I think there are ways that markets can work here, but there are also ways that markets fail here, right? Like, the number one way that markets fail is that it's still, from a human health perspective, better to treat tuberculosis than it is to lengthen eyelashes, but from a market perspective, it's better to lengthen eyelashes than it is to treat tuberculosis, and that's a fundamental disconnect. And the only way to resolve that disconnect, in my opinion, is to have governments or other international authorities involved in reshaping the incentive structure so that it becomes profitable.
14:19 Speaker 02 To treat tuberculosis, more profitable to treat tuberculosis than it is to lengthen eyelashes.
14:23 Speaker 00 What does that mean to change those incentive structures? What needs to happen?
14:27 Speaker 02 So we've seen this a little bit, actually, because between 1945 and 1965, we developed eight classes of drugs to treat tuberculosis because there was a real market incentive to do so. And then between 1965 and 2012, we developed none. And that's the main reason we're in the mess that we're in right now, is those 50 years of failure.
14:46 Speaker 00 What was the market incentive in that first window that disappeared in that second window?
14:50 Speaker 02 Rich people still got tuberculosis in the first window. I think some kind of public-private partnership like that is the way forward. That's the way to do it at scale. That's the way to do it to get the kind of better tools we need. Because it's true that tuberculosis is curable, but we could absolutely have better tools. I mean, the vast majority of people with TB are treated with the same drugs they would have been treated with in 1965. There are very few diseases for which that's the case, right? Like, my brother's cancer was treated very differently in 2023 than it would have been in 1965.
15:22 Speaker 00 So we talk about our having a cure for TB, but the reality is we also do have drug-resistant tuberculosis. And drug-resistant tuberculosis is rising, not falling, right? And so is the threat of the spread of drug-resistant tuberculosis enough to generate the market incentives to spend more to develop new cures nor new approaches to tuberculosis? Or are we not there yet?
15:50 Speaker 02 Unfortunately, it's not enough on its own because, sort of by definition, antibiotics are a real challenge when it comes to incentives, right? Because from a market perspective, you want a drug that everyone takes all the time. And from an antibiotic perspective, you want a drug that almost no one takes, except in cases of everything else failing, so that you can protect the antibiotic. And there's just a disconnect there. We have the same problem. I mean, this is not only a problem with tuberculosis, it's a problem with all bacterial infections. I remember I had orbital cellulitis in 2007, this infection between my eye and my brain. It was quite serious. I ended up spending 10 days in the hospital at NYU. And my infectious disease doctor came in on like the second or third day and said, have you taken a white pill?
16:35 Speaker 02 And I was like, yeah. And he said, did you take a yellow pill? I was like, yeah. He's like, have you taken a green pill? I was like, yeah. And he was like, have you taken a pill that costs $15,700 per pill? And I was like, no. And he was like, well, you're about to. And you can kind of do that in the rich world, right? Where you protect drugs by making them absurdly expensive. But in a country like Sierra Leone, that's a nonstarter. No one will be able to access that medication.
17:00 Speaker 00 I'm about to give you a lot of power. You ready?
17:02 Speaker 02 I'm ready. I'm excited. I mean, and at the same time reluctant, Jeff, like anyone who's given a lot of power ought to be.
17:08 Speaker 00 Well, with great power comes great responsibility. So here we go. You all of a sudden are in charge of the World Health Organization.
17:15 Speaker 02 Great.
17:16 Speaker 00 Where the first steps you're doing to address tuberculosis.
17:19 Speaker 02 Jeff, to be honest with you, I think the first thing that I'm doing is retiring from my position as the head of the World Health Organization.
17:25 Speaker 00 Well done you.
17:25 Speaker 02 Okay, so there's two things that I would do. The World Health Organization has a fundamental problem when it comes to treating tuberculosis, which is limited resources. And the biggest way to fight that is with attention. And so I would go on a huge public relations campaign. I would try to make tuberculosis news again. I would try to make tuberculosis the center of our of our story again. And not just tuberculosis, but also malaria, other diseases of injustice, cholera, typhoid. Go back to a world where people are aware of these diseases. And then the second thing I would do is shift the priorities a little bit so that instead of just waiting until people are so sick that they come into the hospital, at which point their tuberculosis is often very hard to treat, I would do what's called case finding
18:09 Speaker 02 or a massive search and treat program. And this is exactly how we eliminated tuberculosis or nearly eliminated tuberculosis in the United States. We sent out these mobile like Winnebago's with chest X-ray machines inside of them all throughout the country to places where there were high rates of TB. We offered people free chest X-rays and then we gave them free treatment if they were positive for TB. And that's how we did it. And then, so we search, we treat, and then we offer preventative care to those people's close contacts. So we offer one month of preventative antibiotics to their close contacts. So we just stopped that chain of transmission in its tracks and we know that we've stopped it. Now, to start, because of limited resources, we wouldn't be able to do that at scale around the globe, but we would be able to do pilot projects that can prove that you can basically
18:53 Speaker 02 reduce the burden of TB to zero, even in large communities, like whether that's Karachi, Pakistan, or the entire nation of Lesotho.
19:04 Speaker 00 More with John Green about the latest progress and pitfalls in the fight against tuberculosis in just a minute.
19:19 Speaker 00 We all know the disappointment that comes when a grand gesture falls flat, something that seemed impressive in the moment, but didn't deliver the results you expected. Marketing budgets too often fall into that trap, aiming for big impressions, big reach, but without the revenue to back it. LinkedIn has a name for it, Bull Spend. LinkedIn Ads generate the highest ROAS of all major ad networks. They target by company, industry, job title, and more. Spend $250 on your first campaign on LinkedIn Ads and get a $250 credit for the next one. Just go to LinkedIn.com/Scale. That's LinkedIn.com/Scale. Terms and conditions apply.
20:02 Speaker 00 When you've built substantial wealth through your business, it's often tied up in a single equity position. The upside is real, but so is the risk, and knowing when to act isn't always obvious. Creative Planning works with business owners to build a strategy around concentrated equity, when to diversify, how to manage tax risk, and how to protect what you've spent years building. Creative Planning, where wealth works together. Learn more at creativeplanning.com/mastersofscale.
20:33 Speaker 00 Stripe Treasury is your new financial operating system built for what's next. With Stripe Treasury, the place your business accepts payments is also where you can store balances, move funds, and pay vendors worldwide. If you're building for global scale, get a business bank account that lets your money move instantly, whenever and wherever you need it. Learn more at Stripe.com/Treasury. Stripe is not a bank. Banking services provided by Fifth Third Bank, National Association Member FDIC.
21:05 Speaker 00 Welcome back to Masters of Scale. You can find this conversation and more on our YouTube channel. Next set of great responsibility, you may be more reluctant to take this one on.
21:15 Speaker 02 Yeah.
21:16 Speaker 00 But you're now the CEO of Johnson & Johnson.
21:18 Speaker 02 Oh, great. Yeah, I hate that job.
21:20 Speaker 00 Well, you've got it for the next minute or two here. And you still have a responsibility to balance shareholder returns with stakeholder interests here. What are you doing differently than J and J is doing right now?
21:34 Speaker 02 Well, it's really hard because J and J is working within a system, as you say, that that has to prioritize shareholder returns. They have a fiduciary obligation to their shareholders to do so. And yet, they also have a pretty broad spectrum of goods and services that they provide to the market. And so it benefits Johnson and Johnson to live by their values. And to Johnson and Johnson's credit, this is something that they've done.
22:01 Speaker 00 John, can we just go just a little bit deeper on Johnson and Johnson in India? Can you explain what happened with the patent there and what it means for people with TB there?
22:11 Speaker 02 Johnson and Johnson had a patent on bedaquin, this great TB drug. But when their patent expired, they filed secondary patents globally, including in India, to extend the life of that patent, which is a very common thing that pharmaceutical companies do. Some activists from India and South Africa came together to file a lawsuit in India to say, actually, this doesn't involve meaningful innovation and they shouldn't be allowed to file a secondary patent. And they succeeded. And so Johnson and Johnson wasn't able to file a secondary patent in India, which meant that generic competition for bedaquin could emerge in
22:52 Speaker 02 India. The problem was, much of the rest of the world, they had succeeded in filing secondary patents. And so the fight had to continue to make sure that everybody could access bedaquin. But eventually, J and J abandoned all of their secondary patents on bedaquin. And today, the price of it has dropped by over 55% just in the last year. It's an incredible story. What I would do is I would go to my stakeholders, including my biggest shareholders, and I would say, look, we're going to do something slightly out of the box when it comes to disease in really poor countries. And what we're going to do is when we accept public funding for a drug like bedaquin, we are going to charge
23:34 Speaker 02 whatever the heck we please in the United States and Germany and France. And then we're going to provide it at cost in poor countries. And the reason that we're going to do this is because it's going to be a PR win for us, and because it's a win for human health, and it's in line with our values.
23:48 Speaker 00 So why don't they do that?
23:51 Speaker 02 I've tried to make the case.
23:52 Speaker 00 What do you hear when you make that case?
23:54 Speaker 02 The pressure that these folks are under is intense because they're under intense pressure for this quarter and next quarter and the quarter after that. And so what I hear is we're not in a position to do that because we have a responsibility to today's shareholders. My response to that would be the reason Johnson and Johnson is here is often because it hasn't done a good job of meeting the needs of the day, but is instead focused on the long-term future. And that's true for any corporation that's been around for over 100 years. They've shown a resiliency and ability to understand not just the current needs of the market, but the future needs, not just current system of values, but a future system of values. And with J and J in particular, I would point to their founders and the folks who made
24:37 Speaker 02 it possible for J and J to exist, who were quite focused on social justice and making a better world. I think almost everyone who works at pharmaceutical companies or diagnostic companies or any corporation really wants to make life better for people. They want to lower barriers to access. They want to improve healthcare outcomes. And yet we know that there's something wrong, right? We know there's something wrong because life expectancy is falling in the US. And we know that there's something wrong because we're seeing a flattening out of global health improvements. So we know there's a problem.
25:08 Speaker 00 Yeah, I think it's also important to note that this notion that it is financial return above all else as a mission for corporations and obligation for corporate leaders is a relatively new idea. This is only about a 50-year-old idea. And to your point, J and J and many other companies have built century-old businesses in part by focusing on stakeholders other than their shareholders as a key constituency.
25:35 Speaker 02 Absolutely.
25:36 Speaker 00 Yeah, we're seeing companies today that are thriving because they're treating their employees better than other companies and they're thinking about their customers above their their short-term returns. How do you imagine a world in which pharmaceutical companies are leaning more in that direction? How do we get there?
25:52 Speaker 02 I think we get there by. Polite but persistent pressure. And I think we get there through regulation, which I know is a word that many listeners of this podcast hate to hear. And I absolutely understand, look, I have to interact with worlds of regulation all the time. They can be extraordinarily unpleasant. I get that part of it. But if there is nobody pushing back, there is nobody saying, hey, when you accept $500 million of public money, there has to be some public benefit. If nobody's saying that, then we're in trouble.
26:27 Speaker 00 One of the concerns about the United States spending on TB initiatives in other countries is, boy, we got a lot of problems at home. We have crumbling infrastructure. We have environmental issues. We have schools that are underperforming our kids terribly. And we hear it every day. Why should the US be prioritizing TB efforts abroad when we have so many problems at home?
26:53 Speaker 02 Well, first off, I'd just point out that the US has never prioritized TB efforts. The criticism of USAID for many years and other related organizations that are funded by the US government is that the vast majority of that money stays in the US one way or another. It pays farmers, it pays contractors, it pays, you know, very little of that money ends up abroad. And it pays drug manufacturers in the US. And so that's the first thing that I'd say is that it's never been neutral and it's always been oriented toward the interests of the United States. Second thing I'd say is that one of the most effective ways the US has expressed its power over the last 60 years is through its generosity.
27:34 Speaker 02 Just to state the obvious, it's a very different experience to open up a package of lifesaving nutrition bars that's a gift from the people of the United States than it is to experience United States foreign policy in other ways. And so I think this is the best money that we spend and the vast majority of it stays in the US. In fact, I've been critical of how much of it stays in the US. And so that's, that's what I would say in response is we're talking about a rounding error in the federal budget. And the reason we talk about it a lot is because it's politically divisive. But for many decades, I think the reason it was so strongly supported bipartisanly
28:16 Speaker 02 was because it was such a good use of our resources, such a good way to build goodwill around the world.
28:25 Speaker 00 Yeah, we're also creating a gap globally that China is rushing to fill.
28:30 Speaker 02 I think that's so important to understand. I mean, the folks who have been laid off as a result of the USAID cuts, and I don't mean folks in the United States, I mean folks globally, they're being hired immediately and they're being hired by Chinese aid organizations because China still does understand the benefits of soft power.
28:50 Speaker 00 John, one of the threads that links so many of the entrepreneurs who we have on the show and who are in our community is almost no one would choose to do this work. This is a harder path than most, but we are so obsessed with solving a problem or taking on a challenge that we can't not do it.
29:09 Speaker 02 Yeah.
29:10 Speaker 00 I'm curious for you, you know, what are the pros and cons of becoming obsessed with tuberculosis?
29:17 Speaker 02 Well, I am a very obsessive person, and I think one of the benefits of becoming obsessed with it is that we solve the problems we pay attention to. And if we feel like we're paying attention to a problem that not enough other people are paying attention to, that's really exciting in a lot of ways. It's also quite frustrating, right? It means that at dinner, you're a weird company because you only want to talk about one thing. And also, many other people don't yet see how big a problem that one thing is. So that's both a benefit and a cost. I think the biggest cost is you can lose sight of the rest of the world, you know, like. In becoming obsessed with tuberculosis, am I still careful to make room for not just like malaria and HIV? Am I still careful to make room for climate change? Am I still
29:59 Speaker 02 careful to make room for the electrification of ovens or whatever? You know, there's so many problems in the world. You got to remember that there are many, many problems. And just because the one I'm obsessed with happens to be my obsession, doesn't mean that it's the only one that matters. It means that that's where I'm focusing my energy and the hope and expectation that other people are focusing their energy on their big problems.
30:22 Speaker 00 What is success for you in this fight, John?
30:25 Speaker 02 Oh, I would love to live to the day when tuberculosis is not a threat to public health, when tuberculosis is rare and readily cured. I would love to live to see a world where tuberculosis is rare and no longer a global health issue. I would like to see it become like typhoid, a disease that is rare, that doesn't kill a lot of people.
30:47 Speaker 00 Two questions before we wrap. How's Henry doing today?
30:50 Speaker 02 He's doing great. I just talked to him this morning. I talk to him most days and he's a junior at the University of Sierra Leone. He's just finishing his final exams now. I'm so proud of him. He's had to do so much work to recover from not just tuberculosis, but the time he lost to tuberculosis. You know, when everyone else was in secondary school, he was in the hospital. And so he had to work really, really hard to get to university. And he's doing so, so well. He's also a YouTuber. I would be remiss if I didn't say Google Henry Ryder YouTube and subscribe to his YouTube channel. Like any good YouTuber, he reminds me to tell everybody to subscribe every time I talk about him.
31:26 Speaker 00 We will link to his YouTube in our show notes.
31:29 Speaker 02 Oh, amazing. Thank you.
31:30 Speaker 00 It strikes me that when someone hears that a problem can be solved with $25 billion a year, it's just such a big number. You know, the idea of contributing a few dollars to an effort, it feels almost hopeless. You know, it's spitting into the ocean. For folks who want to help and are just daunted by the scale of the problem, what do you say to them? What can they do that can make a difference?
31:55 Speaker 02 Well, first, we do spit into the ocean. You know, you got to do that sometimes. But secondly, I think the biggest thing that can happen right now, and we're starting to see partners in health do this in Lesotho and some other organizations try it as well. Is we need to see blueprints for how this is actually going to happen. We need to see blueprints for dramatic reductions in tuberculosis. And that's not on the scale of billions of dollars. That's on the scale of millions of dollars. That's something that I can help out with, right? That's something that you can do a bake sale that helps out with. And so that's where I think that we really can see a difference at a smaller scale. If we can provide a blueprint for how we eliminate tuberculosis in, say, Lesotho, then that can apply to the entire world. It's just then that's when the big health funders have to come in and help us.
32:40 Speaker 00 Let's hope we get there. Thank you so much for being with us. We appreciate you and all you're doing.
32:44 Speaker 02 Thank you, Jeff. It's been awesome.
32:47 Speaker 00 We've only scratched the surface about the truly fascinating history of tuberculosis. To learn more, make sure to check out John Green's book, Everything is Tuberculosis. I'm Jeff Berman. Thank you for listening.
33:13 Speaker 00 Every business hits the same wall the moment your business outgrows the systems that got you here. Spreadsheets everywhere, five different logins, data scattered across entities that don't even talk to each other. If your finance team spends more time finding data than using it, that's when you need the Intuit ERP. Intuit Enterprise Suite is the AI-native ERP solution that's powerful, painless, and proven, built for businesses scaling fast without the complexity that usually comes with it. From the makers of QuickBooks, learn more at intuit.com/ERP.
33:54 Speaker 00 Before we get to the rest of our conversation today, I want to spend a moment sharing with you about the Masters of Scale Summit, which returns to San Francisco this October 20th to 22nd. So many of us feel overwhelmed right now. It feels like so much of the world is careening and we don't have power. We don't have agency. That's the thing about the Masters of Scale Summit. It's really designed to remind us that we do have agency. Agency to lead, agency to design, to build the relationships and the partnerships that empower us and to make the change that we want to see. We program a stage, we curate an audience, we set a schedule that builds in time for these relationships to be made and to grow so that by the time you leave Summit, you
34:39 Speaker 00 are fired out of a cannon, ready to run through walls to do better in the world with the agency that you actually have. I hope to see you there. Visit mastersofscale.com/summit.
34:57 Speaker 07 Hey listeners, Bob here. If you listen to Rapid Response on Masters of Scale, you may be missing half the show because every Friday, we release a second Rapid Response exclusively in the Rapid Response feed. The guests and topics are just as compelling and timely, from Ford CEO to NASA's administrator to the lessons from the devil wears Prada. It takes about 10 seconds to find. Just search Rapid Response wherever you listen to podcasts and hit follow to make sure you never miss an episode. I hope to see you there.
35:36 Speaker 00 Masters of Scale is a Wait What original. Our executive producer is Eve Tro. Our senior producer is Tricia Bobita. The production team includes Masha Makotunina and Brandon Klein. Our senior talent executive is Stephanie Stern. Mixing and mastering by Aaron Bassinelli and Brian Pugh. Original music by Ryan Holiday. Our head of podcasts is Lital Malad. Visit mastersofscale.com to find the transcript for this episode and to subscribe to our newsletter.
36:17 Speaker 08 Humans will never be more intelligent than AI.
36:20 Speaker 09 There's going to be two types of companies. Those who are great at AI and those that went out of business because they weren't.
36:25 Speaker 10 How do we build a future that is human centered?
36:30 Speaker 11 I'm Rana Elkhayubi. And on my podcast, Pioneers of AI, we answer that question and so many more. As an AI scientist, entrepreneur and investor, I know what it takes to build AI that works for everyone. Every week, I sit down with the pioneers shaping our future. And we take you behind the scenes of the AI that's transforming our lives.
36:55 Speaker 11 Find Pioneers of AI wherever you tune in.
Previous The one trait every leader needs today, with General Stanley McChrystal Next The enterprise AI revolution is underway, with Box’s Aaron Levie Page updated October 16, 2026 · transcript and summary are machine-generated